{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:06:11Z","timestamp":1794081971308,"version":"4.8.0"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Tenalisib (RP6530), a dual phosphoinositide 3-kinase \u03b4\/\u03b3 inhibitor was evaluated in a phase I\/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed\/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with \u22651 prior therapy received Tenalisib orally in a 28-day cycle in doses of 200 to 800 mg twice daily (800 mg in fasting and fed state) in escalation phase (n = 19) and 800 mg twice daily (fasting) in expansion phase (n = 39). The most frequently reported treatment emergent adverse events (TEAE) and related TEAE were fatigue (45%) and transaminase elevations (33%), respectively. Most frequently reported related Grade \u22653 TEAE was transaminase elevation (21%). Two dose-limiting toxicities occurred in the 800 mg fed cohort; hence, 800 mg fasting dose was deemed MTD. Tenalisib was absorbed rapidly with a median half-life of 2.28 h. Overall response rate in 35 evaluable patients was 45.7% (3 complete response (CR); 13 partial response (PR)) and median duration of response was 4.9 months. Responding tumors showed a marked downregulation of CD30, IL-31 and IL-32\u03b1. With an acceptable safety and promising clinical activity, Tenalisib can be a potential therapeutic option for relapsed\/refractory TCL. Currently, a phase I\/II combination study with romidepsin is ongoing.<\/jats:p>","DOI":"10.3390\/cancers12082293","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T04:35:51Z","timestamp":1597638951000},"page":"2293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Phase I\/Ib Study of Tenalisib (RP6530), a Dual PI3K \u03b4\/\u03b3 Inhibitor in Patients with Relapsed\/Refractory T-Cell Lymphoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6403-7449","authenticated-orcid":false,"given":"Auris","family":"Huen","sequence":"first","affiliation":[{"name":"Department of Dermatology, the University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M.","family":"Haverkos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, University of Colorado, Denver, CO 80204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramchandren","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, the University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Devata","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin. Previously with Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine and Dermatology, Chao Family Comprehensive Cancer Center University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Genentech Inc. Previously with Department of Lymphoma and Myeloma, the University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajak J.","family":"Barde","sequence":"additional","affiliation":[{"name":"Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Nair","sequence":"additional","affiliation":[{"name":"Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasi Viswanath","family":"Routhu","sequence":"additional","affiliation":[{"name":"Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikant","family":"Viswanadha","sequence":"additional","affiliation":[{"name":"Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaroop","family":"Vakkalanka","sequence":"additional","affiliation":[{"name":"Rhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, the University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcome","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3348\/kjr.2017.18.1.71","article-title":"T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes","volume":"18","author":"Park","year":"2017","journal-title":"Korean J. Radiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Poggio, T., Duyster, J., and Illert, A.L. (2018). Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas. Cancers, 10.","DOI":"10.3390\/cancers10090339"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/cco.2019.01.02","article-title":"Systemic therapy of cutaneous T-cell lymphoma (CTCL)","volume":"8","author":"Alpdogan","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fmed.2019.00116","article-title":"Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and S\u00e9zary Syndrome","volume":"6","author":"Oka","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Horwitz Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_11","first-page":"859","article-title":"The discovery and development of romidepsin for the treatment of T-cell lymphoma","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"ALCANZA study group. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, openlabel, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-018-0138-7","article-title":"Phosphatidylinositol 3-kinase-\u03b4 (PI3K-\u03b4) is a potential therapeutic target in adult T-cell leukemia-lymphoma","volume":"6","author":"Katsuya","year":"2018","journal-title":"Biomark. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta, gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"A novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood.V122.21.4418.4418","article-title":"RP6530, a dual PI3K\u03b4\/\u03b3 inhibitor, attenutates AKT phosphorylation and induces apoptosis in primary cutaneous T cell lymphoma (CTCL) cells","volume":"22","author":"Lewis","year":"2013","journal-title":"Blood"},{"key":"ref_18","unstructured":"Mao, G., and Viswanadha, S. (2013). Rhizen, Switzerland, Unpublished work."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2019.10.013","article-title":"A first-in-human study of Tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor, in patients with relapsed\/refractory hematologic malignancies: Results from the European study","volume":"20","author":"Delarue","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","unstructured":"(2020, July 15). Compassionate Use Study of Tenalisib (RP6530), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711604."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2018-99-112757","article-title":"Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory lymphoid malignancies","volume":"132","author":"Iyer","year":"2018","journal-title":"Blood"},{"key":"ref_24","unstructured":"(2020, July 14). Duvelisib: Prescribing information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf."},{"key":"ref_25","unstructured":"(2020, July 14). Idelalisib: Prescribing information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206545lbl.pdf."},{"key":"ref_26","unstructured":"(2020, July 15). To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02690727."},{"key":"ref_27","unstructured":"Barde, P. (2016). Rhizen, Switzerland, Unpublished work."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cam4.939","article-title":"Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"6","author":"Foss","year":"2017","journal-title":"Cancer Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00432-008-0440-0","article-title":"Serum-soluble IL-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)","volume":"135","author":"Kitagawa","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/j.clml.2019.03.031","article-title":"High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study","volume":"19","author":"Katoh","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pathog.2016.02.002","article-title":"Biology of peripheral T cell lymphomas\u2014Not otherwise specified: Is something finally happening?","volume":"3","author":"Maura","year":"2016","journal-title":"Pathogenesis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1158\/1078-0432.CCR-05-1513","article-title":"Presence of Circulating CCR10+ T cells and Elevated Serum CTACK\/CCL27 in the Early Stage of Mycosis Fungoides","volume":"12","author":"Fujita","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5314\/wjd.v4.i2.69","article-title":"Mycosis fungoides and sezary syndrome: Role of chemokines and chemokine receptors","volume":"4","author":"Hu","year":"2015","journal-title":"World. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Singer","year":"2015","journal-title":"Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/jid.2013.488","article-title":"The role of IL-32 in cutaneous T-cell lymphoma","volume":"134","author":"Suga","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","unstructured":"(2020, July 15). Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K \u03b4\/\u03b3 Dual Inhibitor in Patients With Relapsed\/Refractory Indolent Non-Hodgkin\u2019s Lymphoma (iNHL), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711578."},{"key":"ref_38","unstructured":"(2020, July 15). Safety and Efficacy of Tenalisib (RP6530) in Combination with Romidepsin in Patients with Relapsed\/Refractory T-cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03770000."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:01:25Z","timestamp":1760176885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082293"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082293","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}